NSCLC

News

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

There's no shortage of cancer immunotherapies trying to knock Merck & Co's Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC).

News

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs F...

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, but can now celebrate a vestry after getting FDA approval for first-in-class lung cancer therapy Exk

News

Merck's targeted lung cancer drug tepotinib wins early acces...

The UK drugs regulator has backed Merck KGaA's MET inhibitor for the treatment of some patients with non-small cell lung cancer under the early access to medicines scheme (EAMS).

News

Amgen nabs speedy approval for first-ever KRAS drug sotorasi...

After decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that inhibits KRAS – a cancer target that for a long time was all-but written o

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen claims FDA okay for would-be Tagrisso rival Rybrevan...

Johnson & Johnson's Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell lung cancer (NSCLC).

News